Lupus Therapeutic Market Is Estimated To Witness High Growth Owing To Increasing Disease Prevalence

lupus therapeutic 

The lupus therapeutic market is estimated to be valued at US$ 3035.59 Mn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.


Market Overview:
Lupus therapeutic products are used for the treatment of systemic lupus erythematosus (SLE), commonly known as lupus. SLE is a chronic autoimmune disease that causes inflammation and tissue damage in various parts of the body including joints, skin kidneys, blood cells, brain, heart and lungs. The disease affects approximately 1.5 million people in the U.S. and drugs therapies help reduce disease symptoms and organ damage.

Market Dynamics:
The lupus therapeutic market is driven by increasing prevalence of SLE globally. According to estimates, around 1.5 million Americans and at least 5 million people worldwide have lupus. It is most common in women aged 15 to 44, with 90% of people with the disease being women. Furthermore, rising R&D investments by key players for development of novel and targeted therapies and rising awareness about disease management are also fueling market growth. However, high treatment costs, availability of alternative treatment methods and lack of FDA approved drugs for certain indications restrain the market growth.

The lupus therapeutic market dynamics include drivers such as increasing disease prevalence globally. The autoimmune disease affects approximately 1.5 million people in the U.S. Rising investments in R&D for novel and targeted therapies is also boosting the market. However, high treatment costs and availability of alternative treatment methods poses challenge. Strict FDA regulations for drug approval further restrains market growth.

SWOT Analysis
Strength: Explain in three sentences
The global lupus therapeutic market is continuously innovating and developing novel drugs and treatment options which helps in effective management of the disease. Moreover, rising awareness programs for lupus are helping patients take informed decisions regarding treatment. Increased diagnostic rates are also benefiting early identification and management of lupus.
Weakness: Explain two weaknesses in three sentences
High treatment and monitoring costs associated with lupus management acts as a barrier, especially in low income countries. Also, lack of approved therapeutic alternatives further limits treatment options for patients with severe or resistant forms of lupus.
Opportunity: Explain two opportunities in three sentences
Growing geriatric population prone to autoimmune disorders like lupus present major opportunities. Furthermore, partnerships between players for fast tracked drug development can further expand the treatment landscape.
Threats: Explain two threats in two sentences
Stringent regulatory processes for novel drug approvals can delay market entries. Emergence of alternative treatment modes can also challenge existing revenue patterns.

Key Takeaways
The Global Lupus Therapeutic Market is expected to witness high growth, exhibiting CAGR of 8.6% over the forecast period, due to increasing prevalence of autoimmune diseases. It is estimated that around 5 million people worldwide suffer from lupus.
Regional analysis: North America region currently dominates the global lupus therapeutic market and is expected to grow at a CAGR of 7.2% during forecast period. This can be attributed to presence of advanced healthcare facilities and growing patient awareness in the region. The Asia Pacific region is expected to exhibit the fastest CAGR of 10.1% during the forecast period due to rising healthcare expenditure and improving diagnostic capabilities in emerging countries like China and India.
Key players: Key players operating in the lupus therapeutic market are Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.

Read More - https://www.dailyprbulletin.com/therapeutics-segment-is-the-largest-segment-driving-the-growth-of-the-lupus-therapeutic-market-share/

 

Comments

Post a Comment

Popular posts from this blog

Training Market Estimated To Witness High Growth Owing To Growing Emphasis on Developing Skillset

Image
  Training Market The Training Market Is Estimated To Be Valued At US$132.2244 Bn In 2023 And Is Expected To Exhibit A CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: The training market covers products and services related to developing and enhancing skills through workshops, online programs and classroom instructions. This includes corporate training focused on technical, soft and safety skills for varied industries. The key end users are corporates, government organizations and educational institutes. Market Dynamics: The training market is expected to witness significant growth owing to growing emphasis on developing skills to cope with rising complexity and changing nature of jobs. With rapid digitalization and emerging technologies, job roles are transforming significantly necessitating continuous upskilling and reskilling of workforce. This is driving increased demand for training p...
Read more

Salmonella Testing Is Estimated To Witness High Growth Owing To Rising Food Safety Concerns

Image
Salmonella testing market The Salmonella testing market is estimated to be valued at US$ 2.91 Bn in 2023 and is expected to exhibit a CAGR of 7.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: The Salmonella testing market involves detection and identification of Salmonella bacteria that causes food poisoning. The key products in the market are assays, kits and reagents that are used to test food samples, clinical samples and environmental samples for the presence of Salmonella. Major end-users include food processing companies, pharmaceutical companies, clinical laboratories and research institutions. Market Dynamics: Rising global outbreaks of foodborne illnesses caused by Salmonella infection is a major factor driving growth of the Salmonella testing market. According to WHO, non-typhoidal Salmonella causes over 90 million cases of gastroenteritis each year globally. Growing consumer awareness abo...
Read more

Global Lab-on-a-Chip and Microarrays (Biochip) Market Is Estimated To Witness High Growth Owing To Rising Demand for Personalized Medicine and Technological Advancements

Image
  Lab-on-a-Chip and Microarrays (Biochip) Market The Lab-on-a-Chip and Microarrays (Biochip) Market is estimated to be valued at US$ 15,268.0 Mn in 2023 and is expected to exhibit a CAGR of 13.43% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Lab-on-a-chip and microarrays (biochip) are innovative technologies that have revolutionized the field of diagnostics and drug discovery. These devices are used for sample analysis and detection of diseases at a molecular level. Lab-on-a-chip platforms offer benefits such as minimal sample requirement, high-throughput analysis, and cost-effective solutions. They find applications in various areas such as genomics, proteomics, and clinical diagnostics, among others. These biochips have the potential to provide personalized medicine by enabling rapid and accurate diagnosis, leading to effective treatments and improved patient outcomes. Market Dynamics: The market ...
Read more